Cheryl Guttman Krader
Developmental dysplasia of the hip
Developmental dysplasia of the hip (DDH) refers to a spectrum of abnormalities that range in severity from mild instability to frank dislocation. The vast majority of clinical and anatomic hip abnormalities identified in early infancy resolve spontaneously. Left untreated, however, a hip that is persistently unstable and anatomically abnormal can lead to functional limitations, pain, and premature degenerative changes.
Urethral lift: 5-year data point to procedure’s durability
Analyses of data from 5 years of prospective follow-up in the pivotal trial supporting regulatory approval of the prostatic urethral lift ([PUL] UroLift System, NeoTract) show that the minimally invasive procedure remains safe and provides rapid and durable benefits for men with symptomatic BPH.
DARPin molecule prolongs anti-VEGF activity in nAMD
A phase III study program investigating abicipar pegol (Allergan) for the treatment of neovascular age-related macular degeneration (nAMD) is underway based on promising efficacy and safety results in phase II studies.
No one imaging tool fits all in identifying AMD lesions
Multimodal imaging, including traditional and newer techniques, is necessary for identifying the spectrum of retinal lesions associated with age-related macular degeneration (AMD), said David Sarraf, MD.
Treating ROP: Laser associated with high success rate for retinopathy of prematurity
Laser photocoagulation is a time-tested, well-defined, and effective treatment for retinopathy of prematurity (ROP) with requirements for follow-up that are much more manageable compared with anti-vascular endothelial growth factor (anti-VEGF) therapy, argued David K. Wallace, MD, MPH.
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I disease
Treating ROP: Substantial benefits make anti-VEGF preferred for Zone I disease
Anti-VEGF therapy for Zone I retinopathy of prematurity (ROP) is associated with better structural and functional outcomes than laser therapy, but also a longer recurrence risk period, said Helen A. Mintz-Hittner, MD.
Insights from anti-VEGF pivotal DME trials
Analyses of data collected in the RISE/RIDE and VIVID/VISTA clinical trials provide important messages about the efficacy and safety of ranibizumab (Lucentis, Genentech) and aflibercept (Eylea, Regeneron) for treatment of diabetic macular edema (DME).

Poll

View Results